Research
Awards Grant
A Phase 1, Open-Label, Dose-escalation trial of CD33xCD3 Bispecific Antibody in Pediatric patients with Relapsed of Refractory Acute Myeloid Leukemia - COG ADVL 2111
A Phase I/II Study of Bosutinib in Pediatric Patients with Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia, Study ITCC-054/COG AAML1921
AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,
AALL1331 - Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467,NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
AAML1831A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations”
ACNS1831 - Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Children with Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) associated Low-Grade Glioma (LGG) (CRADA 02172)
ANBL1531-JDI- A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL),”
APEC1621I -NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
ARST1921, A Safety, Pharmacokinetic and Efficacy Study of a ?-Secretase Inhibitor, Nirogacestat(PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors -AR10441
An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121
COG NCTN Network Group Operations Center
COG NCTN Network Group Operations Center
COG Nursing Committee
COG Scientific Council
COG Scientific Council
Cancer Care Delivery Study Chair
Children's Oncology Group NCTN Network Group Operations
Children's Oncology Group NCTN Network Group Operations
Children's Oncology Group NCTN Network Group Operations
Improving the Reach and Effectiveness of STD Prevention, Screening, and Treatment Services in Local Public Health Systems
Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823
Long-term Follow-up Center to Facilitate Survivorship Research within COG
Long-term Follow-up Center to Facilitate Survivorship Research within COG
NIH National Clinical Trials Network (NCTN) Grant (2U10CA180886) Successor to NIH National Clinical Trials Network (NCTN Grant (U10CA180886)
National Clinical Trials Network (NCTN) Grant (U10CA180886) Study Chair
PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,
PEPN2112- A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
PER CASE REIMBURSEMENT NCORP Operations Grant 7UG1CA189955 -PHI/COG
Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG
Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG
Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
Workload Intensity NIH Nationl Clinical Trials Network (NCTN) Grant (U10DA180886) - PHI/COG
Workload Intensity NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) -PHI/COG
